Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients

References

• Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology43(2 Suppl. 1), S173–S181 (2006).
   PubMed Web of Science ®Google Scholar
• Marion PL. Use of animal models to study hepatitis B virus. Prog. Med. Virol.35, 43–75 (1988).
   PubMedGoogle Scholar
• Korba BE, Gowans EJ, Wells FV, Tennant BC, Clarke R, Gerin JL. Systemic distribution of woodchuck hepatitis virus in the tissues of experimentally infected woodchucks. Virology165(1), 172–181 (1988).
   PubMedGoogle Scholar
• Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell47(3), 451–460 (1986).
   PubMed Web of Science ®Google Scholar
• Le Mire MF, Miller DS, Foster WK, Burrell CJ, Jilbert AR. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection. J. Virol.79(19), 12242–12252 (2005).
   PubMedGoogle Scholar
• Doo E, Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology120(4), 1000–1008 (2001).
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology45(4), 1056–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. N. Engl. J. Med.350(11), 1118–1129 (2004).
   PubMed Web of Science ®Google Scholar
• Ling R, Harrion TJ. Production of hepatitis B virus covalently closed circular DNA in transfected cells is independent of surface antigen synthesis. J. Gen. Virol.78(Pt 6), 1463–1467 (1997).
   PubMedGoogle Scholar
• Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin. Immunopathol.17(2–3), 261–281 (1995).
   PubMedGoogle Scholar
• Guidotti LG, Morris A, Mendez H et al. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J. Virol.76(6), 2617–2621 (2002).
   PubMedGoogle Scholar
• Webster GJ, Reignat S, Maini MK et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology32(5), 1117–1124 (2000).
   PubMed Web of Science ®Google Scholar
• Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med.2(10), 1104–1108 (1996).
   PubMed Web of Science ®Google Scholar
• Liang TJ, Baruch Y, Ben-Porath E et al. Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology13(6), 1044–1051 (1991).
   PubMedGoogle Scholar
• Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation59(2), 230–234 (1995).
   PubMed Web of Science ®Google Scholar
• Liang R, Lau GK, Kwong YL et al. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J. Clin. Oncol.17(1), 394–398 (1999).
   PubMed Web of Science ®Google Scholar
• Markovic S, Drozina G, Vovk M et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology46(29), 2925–2930 (1999).
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Virol.62(3), 299–307 (2000).
   PubMed Web of Science ®Google Scholar
• Tillmann HL, Wedemeyer H, Manns MP et al. Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. J. Hepatol.39(Suppl. 1), S206–S211 (2003).
   Google Scholar
• Su WP, Wen CC, Hsiung CA et al. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J. Gastroenterol.11(34), 5283–5288 (2005).
   PubMedGoogle Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology43(2), 209–220 (2006).
   PubMed Web of Science ®Google Scholar
• Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol. Int.2(2), 152–162 (2008).
   PubMed Web of Science ®Google Scholar
• Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood113(14), 3147–3153 (2009).
   PubMed Web of Science ®Google Scholar
• Hui CK, Sun J, Au WY et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J. Hepatol.42(6), 813–819 (2005).
   PubMed Web of Science ®Google Scholar
• Raimondo G, Allain JP, Brunetto MR et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol.49(4), 652–657 (2008).
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant.15(10), 1143–1238 (2009). Erratum in: Biol. Blood Marrow Transplant.16(2), 294 (2010).
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Baldomero H, Aljurf M et al. Hematopoietic stem cell transplantation: a global perspective. JAMA303(16), 1617–1624 (2010).
   PubMed Web of Science ®Google Scholar
• Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J. Gastroenterol. Hepatol.17(4), 409–414 (2002).
   PubMedGoogle Scholar
• Dhedin N, Douvin C, Kuentz M et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation66(5), 616–619 (1998).
   PubMed Web of Science ®Google Scholar
• Hui CK, Lie A, Au WY et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood106(2), 464–469 (2005).
   PubMedGoogle Scholar
• Seth P, Alrajhi AA, Kagevi I et al. Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease. Bone Marrow Transplant.30(3), 189–194 (2002).
   PubMedGoogle Scholar
• Lau GK, Liang R, Lee CK, Lim WL. Is vaccination of donor adequate for clearance of hepatitis B virus after bone-marrow transplantation? Lancet349(9065), 1626–1627 (1997).
   PubMedGoogle Scholar
• Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.15(9), 1049–1059 (2009).
   PubMed Web of Science ®Google Scholar
• Aksoy S, Harputluoglu H, Kilickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk. Lymphoma48(7), 1307–1312 (2007).
   PubMed Web of Science ®Google Scholar
• Moses SE, Lim ZY, Sudhanva M et al. Lamivudine prophylaxis and treatment of hepatitis B virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J. Med. Virol.78(12), 1560–1563 (2006).
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc. Natl Acad. Sci. USA83(6), 1627–1631 (1986).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology45(2), 507–539 (2007). Erratum in: Hepatology45(6), 1347 (2007).
   PubMed Web of Science ®Google Scholar
• European Association for the study of the liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol.50(2), 227–242 (2009).
   PubMed Web of Science ®Google Scholar
• Koo S, Baden LR. Infectious complications associated with immunomodulating monoclonal antibodies used in the treatment of hematologic malignancy. J. Natl Compr. Canc. Netw.6(2), 202–213 (2008).
   PubMedGoogle Scholar
• Iannitto E, Minardi V, Calvaruso G et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur. J. Haematol.74(3), 254–258 (2005). Erratum in: Eur. J. Haematol.75(2), 183 (2005).
   PubMed Web of Science ®Google Scholar
• Ramos CA, Saliba RM, de Pádua Silva L et al. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.16(5), 686–694 (2010).
   PubMedGoogle Scholar
• Idilman R. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy. J. Antimicrob. Chemother.55(6), 828–831 (2005).
   PubMed Web of Science ®Google Scholar
• Li YH, He YF, Jiang WQ et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer106(6), 1320–1325 (2006).
   PubMed Web of Science ®Google Scholar
• Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology46(4), 1049–1056 (2007).
   PubMed Web of Science ®Google Scholar
• Pérez-Roldán F, González-Carro P, Villafáñez-García MC. Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N. Engl. J. Med.352(3), 310–311 (2005).
   PubMedGoogle Scholar
• Fouillard L, Serfaty L, Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant.37(6), 625–626 (2006).
   PubMedGoogle Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology50(3), 661–662 (2009).
   PubMed Web of Science ®Google Scholar
• Hui CK, Cheung WW, Au WY et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut54(11), 1597–1603 (2005).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology119(1), 172–180 (2000).
   PubMed Web of Science ®Google Scholar
• Westland CE, Yang H, Delaney WE 4th et al. Week 48 resistance surveillance in two Phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology38(1), 96–103 (2003).
   PubMed Web of Science ®Google Scholar
• Opio CK, Lee WM, Kirkpatrick P. Entecavir. Nat. Rev. Drug Discov.4(7), 535–536 (2005).
   PubMedGoogle Scholar
• Angus P, Vaughan R, Xiong S et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology125(2), 292–297 (2003).
   PubMed Web of Science ®Google Scholar
• Villeneuve JP, Durantel D, Durantel S et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol.39(6), 1085–1089 (2003).
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Viganò M, Zilioli VR et al. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J. Clin. Virol.35(4), 467–469 (2006).
   PubMed Web of Science ®Google Scholar
• Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin. Liver Dis.11, 869–892 (2007).
   PubMedGoogle Scholar
• Bohne F, Chmielewski M, Ebert G et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology134(1), 239–247 (2008).
   PubMed Web of Science ®Google Scholar
• Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc. Natl Acad. Sci. USA102(3), 773–778 (2005).
   PubMed Web of Science ®Google Scholar